Details of the Drug Reposition

General Information of This Drug (ID: DMAB9QE)

• Drug Name: Nivolumab (DMAB9QE)
• Drug Type: Monoclonal antibody

Information on Drug Reposition of This Drug

2 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Melanoma	DIS1RRCY	2C30	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Approved	[2]

6 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Recurrent glioblastoma	DISHYPKS	2A00.00	Phase 3	[3]
Multiple myeloma	DISEWP9B	2A83	Phase 3	[3]
Esophageal cancer	DISGB2VN	2B70	Phase 3	[3]
Gastric adenocarcinoma	DISWWLTC	2B72	Phase 3	[3]
Small-cell lung cancer	DISK3LZD	2C25.Y	Phase 3	[3]
Malignant pleural mesothelioma	DIST2R60	2C26.0	Phase 3	[3]

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Follicular lymphoma	DISVEUR6	2A80	Phase 2	[3]
Diffuse large B-cell lymphoma	DISSACK3	2A81	Phase 2	[3]
Central nervous system lymphoma	DISBYQTA	2B33.5	Phase 2	[3]
Prostate cancer	DISF190Y	2C82.0	Phase 2	[3]

3 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pancreatic cancer	DISJC981	2C10	Phase 1/2	[3]
Triple negative breast cancer	DISAMG6N	2C60-2C65	Phase 1/2	[3]
Ovarian cancer	DISZJHAP	2C73	Phase 1/2	[3]

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Chronic myelogenous leukaemia	DIS0301E	2A20.0	Phase 1	[3]

1 Application submitted Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Renal cell carcinoma	DISQZ2X8	2C90	Application submitted	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
• [2] COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)